Concepedia

Susanne Muehlbauer

SM

7

Publications

1.9K

Citations

7

H-Index

2007

Active since

Affiliations

Roche (Switzerland)(Current)

Institut Paoli-Calmettes

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Sana Klinikum Offenbach

Asan Medical Center

Susanne Muehlbauer is an author at Roche (Switzerland) specializing in radiation oncology, medicine, and oncology.

ORCID

Top concepts

Publications per year

2007–2022

7

Publications

7

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

Luca Gianni, Urania Dafni, Richard D. Gelber et al. · The Lancet Oncology · 2011 · 611 citations

, , +5

Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial

Thomas Suter, Marion Procter, Dirk J. van Veldhuisen et al. · Journal of Clinical Oncology · 2007 · 563 citations · Full text

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

Gustavo Ismael, Roberto Hegg, Susanne Muehlbauer et al. · The Lancet Oncology · 2012 · 337 citations

, , +6

Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial

Marion Procter, Thomas Suter, Evandro de Azambuja et al. · Journal of Clinical Oncology · 2010 · 244 citations

Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial

Marina Konopleva, Christoph Röllig, Jamie Cavenagh et al. · Blood Advances · 2022 · 68 citations · Full text

Rows per page

1–5 of 7